Novartis (CH)

Alle Meldungen

24.11

Novartis (CH) Novartis (CH)

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Longer-term 96-week results from Scemblix ® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali ® * 4-year analysis on distant disease-free survival in key...

Zur Pressemeldung auf www.novartis.com
29.10

Novartis (CH) Novartis (CH)

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies 1-3 Patients on Scemblix also had fewer dose...

Zur Pressemeldung auf www.novartis.com
26.10

Novartis (CH) Novartis (CH)

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months 1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – vs. patients' historic rapid...

Zur Pressemeldung auf www.novartis.com
24.10

Novartis (CH) Novartis (CH)

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA 1 Recommendation comes after recent...

Zur Pressemeldung auf www.novartis.com
18.10

Novartis (CH) Novartis (CH)

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination...

Zur Pressemeldung auf www.novartis.com
18.09

Novartis (CH) Novartis (CH)

New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients

Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study 1 More than 80% of patients receiving first-line Kesimpta were...

Zur Pressemeldung auf www.novartis.com
17.09

Novartis (CH) Novartis (CH)

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer

Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2 Kisqali ® (ribociclib) significantly reduced the risk of...

Zur Pressemeldung auf www.novartis.com
16.09

Novartis (CH) Novartis (CH)

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer

Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease 1 Results remain consistent across secondary endpoints,...

Zur Pressemeldung auf www.novartis.com
04.09

Novartis (CH) Novartis (CH)

Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network

Indianapolis site expansion will establish in-house production of isotopes critical for production of radioligand therapies (RLTs) for cancer treatment New facility in California will be third US-based RLT production facility Novartis is...

Zur Pressemeldung auf www.novartis.com
15.08

Novartis (CH) Novartis (CH)

Novartis statement on Maximum Fair Price for Entresto

Aug 15, 2024 Novartis believes the price-setting provisions in the IRA are unconstitutional and will have long-lasting and devastating consequences for patients by limiting access to medicines now and in the future. We acceded to a “maximum fair...

Zur Pressemeldung auf www.novartis.com

Wem folgen?

Verbund
Folgen
ServusTV
Folgen
Canon
Folgen

Mehr anzeigen

Trends

Black Friday
Folgen
Tesla
Folgen
Menschenrechte
Folgen
Advent
Folgen
Home Office
Folgen
Aktionstag
Folgen
Fachkräftemangel
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info